CardiovascularBusiness -- After much debate on whether or not diabetes drug rosiglitazone (Avandia, GlaxoSmithKline) should be pulled from the shelves due to its potential to cause increased cardiovascular risk in patients, results of a recent study have shown that the risk of MI, heart failure (HF) or death in patients administered either rosiglitazone or pioglitazone (Actos, Takeda) were similar--almost 4 percent.
